Marbocyl P 20 mg ad us. vet.

Hauptinformation

  • Handelsname:
  • Marbocyl P 20 mg ad us. vet., teilbare Tabletten
  • Darreichungsform:
  • teilbare Tabletten
  • Verwenden für:
  • Tiere
  • Art der Medizin:
  • allopathic Droge

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Marbocyl P 20 mg ad us. vet., teilbare Tabletten
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Antibiotikum (Gyrasehemmer) für Hunde und Katzen

Weitere Informationen

Status

  • Quelle:
  • Institut für Veterinärpharmakologie
  • Zulassungsnummer:
  • 56899
  • Letzte Änderung:
  • 02-09-2017

Packungsbeilage: zusammensetzung, kinische angaben, nebenwirkungen, wechselwirkungen, dosierung, schwangerschaft, stillzeit

Marbocyl P 20 mg ad us. vet., teilbare Tabletten

Vetoquinol AG

Antibiotikum (Gyrasehemmer) für Hunde und Katzen

ATCvet: QJ01MA93

Zusammensetzung

Marbofloxacinum20 mg

Aromatica

Excipiens pro compresso

Fachinformationen Wirkstoffe (CliniPharm)

Marbofloxacin

Eigenschaften / Wirkungen

Marbofloxacin ist ein synthetisches bakterizides Antiinfektionsmittel aus der Gruppe der

Fluorochinolone, das durch Hemmung der DNS-Gyrase wirkt. Marbofloxacin weist ein sehr

breites Wirkungsspektrum gegen gramnegative Keime sowie gegen die meisten

Mykoplasmen und grampositiven Erreger auf (bestimmte Streptokokken und Enterokokken

sind resistent). Anaerobier und Pilze sind gegen Marbofloxacin resistent.

Pharmakokinetik

Nach oraler Verabreichung der empfohlenen Dosis von 2 mg/kg wird Marbofloxacin bei

Hund und Katze rasch absorbiert. Maximale Serumspiegel von 1,5 μg/ml werden ungefährg/ml werden ungefähr

nach zwei Stunden erreicht. Die Bioverfügbarkeit beträgt nahezu 100%. In den meisten

Geweben (Haut, Muskel, Leber, Niere, Lunge, Blase und Verdauungstrakt) sind die

Gewebekonzentrationen höher als die Plasmakonzentration. Marbofloxacin wird langsam

ausgeschieden (Halbwertszeit 14 Stunden beim Hund und 10 Stunden bei der Katze) und

grösstenteils in aktiver Form über den Urin (⁄) und Kot (⁄).

Indikationen

Infektionen mit Marbofloxacin-empfindlichen Erregern

-Oberflächliche und tiefe Pyodermien bei Hund und Katze

-Bakterielle Atemwegsinfektion bei Hund und Katze

Harnwegsinfektion mit Proteus mirabilis und E. coli, mit oder ohne begleitende Prostatitis,

Epididymitis beim Hund

Empfohlene Dosierung 2 mg/kg einmal täglich

1 Tablette zu 5 mg für 2,5 kg KGW pro Tag

1 Tablette zu 20 mg für 10 kg KGW pro Tag

1 Tablette zu 80 mg für 40 kg KGW pro Tag

Hunde

Pyodermien mind. 5 Tage; je nach klinischem Verlauf bis zu 40 Tage

Akute Atemwegsinfektion 7 Tage; chronische 21 Tage

Harnwegsinfektion ohne Prostatitis oder Epididymitis mind. 10 Tage; übrige Fälle 28 Tage

Katzen

Infektion von Haut und subkutanen Gewebe 3 bis 5 Tage

Atemwegsinfektion 5 Tage

Anwendungseinschränkungen

Kontraindikationen

Marbofloxacin sollte bei grossen Hunden, die weniger als 12 Monate alt sind, nicht

angewendet werden, da die Gefahr einer degenerativen Schädigung des Gelenkknorpels

besteht. Bei mittelgrossen Rassen im Wachstum wird Marbofloxacin bei Gaben von bis zu

6 mg/kg/Tag während 13 Wochen gut vertragen.

Vorsichtsmassnahmen

Marbocyl P 5 mg/20 mg/80 mg ad us. vet. Tabletten sollen nur nach vorheriger

bakteriologischer Sicherung der Diagnose und Sensitivitätsprüfung der beteiligten Erreger

sowie bei Vorliegen von Resistenzen gegenüber anderen Antibiotika angewendet werden.

Der Einsatz von Marbocyl P 5 mg/20 mg/80 mg ad us. vet. Tabletten, wie der aller

Fluorochinolone, sollte aus Gründen einer möglichen Resistenzentwicklung nicht bei

geringfügigen Infektionen erfolgen.

Unerwünschte Wirkungen

VetVigilance: Pharmacovigilance-Meldung erstatten

In seltenen Fällen können Nebenwirkungen wie Erbrechen, weicher Kot, verändertes

Durstgefühl und Hyperaktivität auftreten. Diese Nebenwirkungen verschwinden aber

spontan wieder.

Wechselwirkungen

Bei gleichzeitiger oraler Verabreichung von Kationen (Aluminium, Kalzium, Eisen,

Magnesium) kann die Bioverfügbarkeit von Marbofloxacin verringert sein.

Sonstige Hinweise

Ausserhalb der Reichweite von Kindern aufbewahren.

Bei Raumtemperatur (15 - 25 °C) aufbewahren.

Packungen

Schachtel mit 10 und 100 Tabletten

Abgabekategorie: A

Swissmedic Nr. 56'899

Informationsstand: 07/2009

Dieser Text ist behördlich genehmigt.

24-1-2019

General Mills Recalls Five Pound Bags of Gold Medal Unbleached Flour

General Mills Recalls Five Pound Bags of Gold Medal Unbleached Flour

General Mills announced today a voluntary national recall of five-pound bags of its Gold Medal Unbleached Flour with a better if used by date of April 20, 2020. The recall is being issued for the potential presence of Salmonella which was discovered during sampling of the five-pound bag product.

FDA - U.S. Food and Drug Administration

17-1-2019

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Safety and efficacy of 8‐mercapto‐p‐menthan‐3‐one and p‐menth‐1‐ene‐8‐thiol belonging to chemical group 20 when used as flavourings for all animal species

Published on: Wed, 16 Jan 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of two compounds belonging to chemical group 20 (aliphatic and aromatic mono‐ and di‐thiols and mono‐, di‐, tri‐, and polysulfides with or without additional oxygenated functional groups). 8‐Mercapto‐p‐menthan‐3‐one [12.038] and p‐menth‐1‐ene‐8‐thiol [12.085] are currently ...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-1-2019

Safety and efficacy of Deccox® (decoquinate) for chickens for fattening

Safety and efficacy of Deccox® (decoquinate) for chickens for fattening

Published on: Mon, 14 Jan 2019 Deccox®, containing decoquinate as the active substance, is a feed additive intended to be used for the prevention of coccidiosis in chickens for fattening at a dose range of 20–40 mg/kg complete feed. Decoquinate from Deccox® is safe for chickens for fattening at the highest applied concentration in complete feed of 40 mg/kg. No practically relevant interactions with other additives or veterinary drugs exist except with bentonite. Decoquinate does not have antibacterial a...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-1-2019

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Safety evaluation of the food enzyme alpha‐amylase from a genetically modified Trichoderma reesei (strain DP‐Nzb48)

Published on: Wed, 09 Jan 2019 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with a genetically modified strain of Trichoderma reesei by Danisco US Inc. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organic solids (TOS) are removed by distill...

Europe - EFSA - European Food Safety Authority EFSA Journal

8-1-2019

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. Issues Voluntary Nationwide Recall of Vecuronium Bromide for Injection Due to the Presence of Particulate Matter Identified as Glass

Sun Pharmaceutical Industries, Inc. (SPII), a wholly owned subsidiary of Sun Pharmaceutical Industries, Ltd. is voluntarily recalling three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder) to the hospital level. The Vecuronium Bromide for Injection has been found to contain particulate matter identified as glass.

FDA - U.S. Food and Drug Administration

21-12-2018

Peer review of the pesticide risk assessment of the active substance propanil

Peer review of the pesticide risk assessment of the active substance propanil

Published on: Thu, 20 Dec 2018 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State Italy for the pesticide active substance propanil and the assessment of applications for maximum residue levels (MRLs) are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of t...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-12-2018

Avian influenza overview August – November 2018

Avian influenza overview August – November 2018

Published on: Thu, 20 Dec 2018 Between 16 August and 15 November 2018, 14 highly pathogenic avian influenza (HPAI) A(H5N8) outbreaks in poultry establishments in Bulgaria and seven HPAI A(H5N6) outbreaks, one in captive birds in Germany and six in wild birds in Denmark and the Netherlands were reported in the European Union (EU). No human infection due to HPAI A(H5N8) and A(H5N6) viruses have been reported in Europe so far. Seroconversion of people exposed during outbreaks in Russia has been reported in...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-12-2018

Ampi-Kur ad us. vet., Eutersuspension

Ampi-Kur ad us. vet., Eutersuspension

● Die Zulassung ist am 21.12.2018 erloschen.

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus DHPPi/L4 ad us. vet.

Versican Plus DHPPi/L4 ad us. vet.

● Änderung Text "Kurzbezeichnung", "Zusammensetzung", "Indikation", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen", "Wechselwirkungen", "Sonstige Hinweise" und "Packungen"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus DHPPi/L4R ad us. vet.

Versican Plus DHPPi/L4R ad us. vet.

● Änderung Text "Zusammensetzung", "Indikation", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen", "Wechselwirkungen", "Sonstige Hinweise" und "Packungen"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus L4 ad us. vet.

Versican Plus L4 ad us. vet.

● Änderung Text "Eigenschaften", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen", "Wechselwirkungen" und "Sonstige Hinweise"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Versican Plus Pi/L4 ad us. vet.

Versican Plus Pi/L4 ad us. vet.

● Änderung Text "Kurzbezeichnung", "Zusammensetzung", "Indikationen", "Dosierung / Anwendung", "Anwendungseinschränkungen", "Unerwünschte Wirkungen" und "Wechselwirkungen"

Institut für Veterinärpharmakologie und toxikologie

20-12-2018

Perlutex ad us. vet., Tabletten

Perlutex ad us. vet., Tabletten

● Änderung Text "Zusammensetzung", "Dosierung / Anwendung" und "Sonstige Hinweise"

Institut für Veterinärpharmakologie und toxikologie

18-12-2018

Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard

Enovachem Pharmaceuticals Issues Voluntary Nationwide Recall of Dyural-40 and Dyural-80 Convenience Kits Containing Recalled Sodium Chloride Injection, USP, 0.9% Due to Latex Hazard

Torrance, CA, Asclemed USA Inc is voluntarily recalling 20 lots of Dyural-40 and 61 lots of Dyural-80, to the user level. The products include recalled Sodium Chloride, USP, 0.9% manufactured by Fresenius Kabi, which has been recalled due to product labeling incorrectly stating stoppers do not contain latex.

FDA - U.S. Food and Drug Administration

17-12-2018


Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Draft cabozantinib tablet 20 mg, 40 mg and 60 mg, capsule 20 4 mg and 80 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

15-12-2018

Schauma-Dip ad us. vet., Zitzendesinfektionsmittel

Schauma-Dip ad us. vet., Zitzendesinfektionsmittel

● Neue Zulassungsinhaberin: Halag Chemie AG

Institut für Veterinärpharmakologie und toxikologie

14-12-2018

Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food

Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food

Published on: Thu, 13 Dec 2018 The European Commission asked EFSA for a scientific evaluation on the risks to human health related to the presence of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in food. Regarding PFOS and PFOA occurrence, the final data set available for dietary exposure assessment contained a total of 20,019 analytical results (PFOS n = 10,191 and PFOA n = 9,828). There were large differences between upper and lower bound exposure due to analytical methods with i...

Europe - EFSA - European Food Safety Authority Publications

14-12-2018

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Analysis of hunting statistics collection frameworks for wild boar across Europe and proposals for improving the harmonisation of data collection

Published on: Thu, 13 Dec 2018 Heterogeneities in the wild boar data collection frameworks across Europe were analysed using questionnaires to explore comparability of hunting data in the short term and propose a common framework for future collection. Fifty‐seven respondents representing 32 countries covering more than 95% of European territory participated to the questionnaire. The most frequently recorded information in the official statistics included the quantity of animals shot per hunting ground ...

Europe - EFSA - European Food Safety Authority Publications

14-12-2018

Bovilis BTV8 ad us. vet.

Bovilis BTV8 ad us. vet.

● Die Zulassung ist am 14.12.2018 erloschen.

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund XS ad us. vet., insektizide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund XS ad us. vet., insektizide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund S ad us. vet., insektizide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund S ad us. vet., insektizide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

12-12-2018

Activyl TickPlus spot-on Hund M ad us. vet., insektizide Loesung zum Auftragen auf die Haut

Activyl TickPlus spot-on Hund M ad us. vet., insektizide Loesung zum Auftragen auf die Haut

● Umwandlung in Exportzulassung (Exportspezialität): nur für den Vertrieb im Ausland

Institut für Veterinärpharmakologie und toxikologie

23-1-2019


Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem

Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem

Orphan designation: Allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells, Treatment in haematopoietic stem cell transplantation, 20/03/2017, Positive

Europe - EMA - European Medicines Agency

22-1-2019


Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Orphan designation: 17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione, Treatment of Duchenne muscular dystrophy, 22/08/2014, Positive

Europe - EMA - European Medicines Agency

16-1-2019

EU/3/14/1309 (Pharma Gateway AB)

EU/3/14/1309 (Pharma Gateway AB)

EU/3/14/1309 (Active substance: 17a,21-dihydroxy-16a-methyl-pregna-1,4,9(11)-triene-3,20-dione) - Transfer of orphan designation - Commission Decision (2019)232 of Wed, 16 Jan 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000002736

Europe -DG Health and Food Safety

14-1-2019

Manyper 10 mg/20 mg Tabletten

Rote - Liste

10-1-2019

Mozobil® 20 mg/ml Injektionslösung

Rote - Liste

4-1-2019

Thybon® 20/100 Henning

Rote - Liste

24-12-2018

ACCM meeting statement, Meeting 20, 16 November 2018

ACCM meeting statement, Meeting 20, 16 November 2018

ACCM meeting statement for 16 November 2018 published

Therapeutic Goods Administration - Australia

21-12-2018

Consultation: Fees and charges proposal 2019-20

Consultation: Fees and charges proposal 2019-20

The TGA is seeking comments from interested parties on the proposed changes in fees and charges for 2019-2020. Closing date: 8 February 2018

Therapeutic Goods Administration - Australia

20-12-2018

.@US_FDA provides an update on new steps to revise #Essure's post-market study to collect long-term safety information following discontinuation of its U.S. sales. Read FDA Commissioner @SGottliebFDA's statement on the new steps here:  https://go.usa.gov/

.@US_FDA provides an update on new steps to revise #Essure's post-market study to collect long-term safety information following discontinuation of its U.S. sales. Read FDA Commissioner @SGottliebFDA's statement on the new steps here: https://go.usa.gov/

. @US_FDA provides an update on new steps to revise #Essure's post-market study to collect long-term safety information following discontinuation of its U.S. sales. Read FDA Commissioner @SGottliebFDA's statement on the new steps here: https://go.usa.gov/xEaNB  #MedicalDevice

FDA - U.S. Food and Drug Administration

20-12-2018

Namuscla (Lupin Europe GmbH)

Namuscla (Lupin Europe GmbH)

Namuscla (Active substance: Mexiletine) - New authorisation - Commission Decision (2018)9133 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4584

Europe -DG Health and Food Safety

20-12-2018

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (AstraZeneca AB)

Bevespi Aerosphere (Active substance: glycopyrronium bromide / formoterol) - New authorisation - Commission Decision (2018)9127 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4245

Europe -DG Health and Food Safety

20-12-2018

Ravicti (Horizon Pharma Ireland Limited)

Ravicti (Horizon Pharma Ireland Limited)

Ravicti (Active substance: Glycerol phenylbutyrate) - Centralised - 2-Monthly update - Commission Decision (2018)9126 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3822/II/19

Europe -DG Health and Food Safety

20-12-2018

Mabthera (Roche Registration GmbH)

Mabthera (Roche Registration GmbH)

Mabthera (Active substance: Rituximab) - Centralised - 2-Monthly update - Commission Decision (2018)9125 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/165/II/149

Europe -DG Health and Food Safety

20-12-2018

Vectibix (Amgen Europe B.V.)

Vectibix (Amgen Europe B.V.)

Vectibix (Active substance: panitumumab) - Centralised - Yearly update - Commission Decision (2018)9135 of Thu, 20 Dec 2018

Europe -DG Health and Food Safety

20-12-2018

Nobilis IB Primo QX (Intervet International B.V.)

Nobilis IB Primo QX (Intervet International B.V.)

Nobilis IB Primo QX (Active substance: Live avian infectious bronchitis virus, strain D388) - Centralised - Yearly update - Commission Decision (2018)9136 of Thu, 20 Dec 2018

Europe -DG Health and Food Safety

20-12-2018

Ledaga (Helsinn Birex Pharmaceuticals Ltd.)

Ledaga (Helsinn Birex Pharmaceuticals Ltd.)

Ledaga (Active substance: chlormethine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)9124 of Thu, 20 Dec 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2826/T/8

Europe -DG Health and Food Safety

20-12-2018

Coxevac (Ceva SantE Animale)

Coxevac (Ceva SantE Animale)

Coxevac (Active substance: Inactivated Coxiella burnetii vaccine) - Centralised - Yearly update - Commission Decision (2018)9072 of Thu, 20 Dec 2018

Europe -DG Health and Food Safety

20-12-2018

Amyvid (Eli Lilly Nederland B.V.)

Amyvid (Eli Lilly Nederland B.V.)

Amyvid (Active substance: Florbetapir (18F)) - Centralised - Yearly update - Commission Decision (2018)9134 of Thu, 20 Dec 2018

Europe -DG Health and Food Safety

19-12-2018

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar:  https://go.usa.gov/xExHX  #MedicalDevice #FDApic.twitter.com/sHElqFFODy

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar: https://go.usa.gov/xExHX  #MedicalDevice #FDApic.twitter.com/sHElqFFODy

Join us on January 17, 2019 from 1-2:30 PM EST for a webinar to help clarify the Breakthrough Devices Program final guidance for manufacturers. Find out more about the webinar: https://go.usa.gov/xExHX  #MedicalDevice #FDA pic.twitter.com/sHElqFFODy

FDA - U.S. Food and Drug Administration

19-12-2018

On Dec. 18th, the @US_FDA issued the final guidance on the Breakthrough Devices Program. The guidance outlines program policies, features, and the process for manufacturers to follow when choosing to pursue the #breakthrough designation. Read more:  https

On Dec. 18th, the @US_FDA issued the final guidance on the Breakthrough Devices Program. The guidance outlines program policies, features, and the process for manufacturers to follow when choosing to pursue the #breakthrough designation. Read more: https

On Dec. 18th, the @US_FDA issued the final guidance on the Breakthrough Devices Program. The guidance outlines program policies, features, and the process for manufacturers to follow when choosing to pursue the #breakthrough designation. Read more: https://go.usa.gov/xExHq  pic.twitter.com/fAAZAQx1H5

FDA - U.S. Food and Drug Administration

19-12-2018

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall:  https://go.usa.gov/

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall: https://go.usa.gov/

On 12/12/18 GE Healthcare Recalled CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA has identified this as a Class I Recall, the most serious type recall. Read more about the recall: https://go.usa.gov/xE383  #MedicalDevice #FDA pic.twitter.com/S2EbMdmwpe

FDA - U.S. Food and Drug Administration

18-12-2018

#DYK December is #SafeToysAndGiftsMonth. Check out @US_FDA's Consumer Update on how to keep kids safe with toys containing lasers:  https://go.usa.gov/xEx2r  #FDApic.twitter.com/57pZAmSb9r

#DYK December is #SafeToysAndGiftsMonth. Check out @US_FDA's Consumer Update on how to keep kids safe with toys containing lasers: https://go.usa.gov/xEx2r  #FDApic.twitter.com/57pZAmSb9r

#DYK December is #SafeToysAndGiftsMonth. Check out @US_FDA's Consumer Update on how to keep kids safe with toys containing lasers: https://go.usa.gov/xEx2r  #FDA pic.twitter.com/57pZAmSb9r

FDA - U.S. Food and Drug Administration

18-12-2018


Human medicines European public assessment report (EPAR): Vabomere, meropenem / vaborbactam, Urinary Tract Infections,Bacteremia,Bacterial Infections,Respiratory Tract Infections,Pneumonia,Pneumonia, Ventilator-Associated, Date of authorisation: 20/11/20

Human medicines European public assessment report (EPAR): Vabomere, meropenem / vaborbactam, Urinary Tract Infections,Bacteremia,Bacterial Infections,Respiratory Tract Infections,Pneumonia,Pneumonia, Ventilator-Associated, Date of authorisation: 20/11/20

Human medicines European public assessment report (EPAR): Vabomere, meropenem / vaborbactam, Urinary Tract Infections,Bacteremia,Bacterial Infections,Respiratory Tract Infections,Pneumonia,Pneumonia, Ventilator-Associated, Date of authorisation: 20/11/2018, Status: Authorised

Europe - EMA - European Medicines Agency

18-12-2018


Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Opioid-Related Disorders, Date of authorisation: 20/11/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Opioid-Related Disorders, Date of authorisation: 20/11/2018, Status: Authorised

Human medicines European public assessment report (EPAR): Buvidal, buprenorphine, Opioid-Related Disorders, Date of authorisation: 20/11/2018, Status: Authorised

Europe - EMA - European Medicines Agency

14-12-2018

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here:  https://go.usa.gov/xE38

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here: https://go.usa.gov/xE38

GE Healthcare Recalls CareScape R860 Inspiratory Safety Guard Due to Risk of Disconnection from Breathing Circuit. @US_FDA @US has identified this as a Class I Recall, the most serious type recall. Read more about the recall here: https://go.usa.gov/xE383  #MedicalDevice #FDA pic.twitter.com/X4IprwU8R2

FDA - U.S. Food and Drug Administration

14-12-2018

#ICYMI: @US_FDA cleared a mobile medical app to help those with #opioid use disorder stay in recovery programs. Read more about the clearance here:  https://go.usa.gov/xE3ke  #FDA #MedicalDevice

#ICYMI: @US_FDA cleared a mobile medical app to help those with #opioid use disorder stay in recovery programs. Read more about the clearance here: https://go.usa.gov/xE3ke  #FDA #MedicalDevice

#ICYMI: @US_FDA cleared a mobile medical app to help those with #opioid use disorder stay in recovery programs. Read more about the clearance here: https://go.usa.gov/xE3ke  #FDA #MedicalDevice

FDA - U.S. Food and Drug Administration

14-12-2018

Minoxicutan Frauen 20 mg/ml

Rote - Liste

14-12-2018

Seroxat 20 mg Filmtabletten

Rote - Liste

12-12-2018


Human medicines European public assessment report (EPAR): Exondys, eteplirsen, Muscular Dystrophy, Duchenne, Date of refusal: 20/09/2018, Status: Refused

Human medicines European public assessment report (EPAR): Exondys, eteplirsen, Muscular Dystrophy, Duchenne, Date of refusal: 20/09/2018, Status: Refused

Human medicines European public assessment report (EPAR): Exondys, eteplirsen, Muscular Dystrophy, Duchenne, Date of refusal: 20/09/2018, Status: Refused

Europe - EMA - European Medicines Agency

12-12-2018

Venofer 20 mg Fe/ml Injektionslösung

Rote - Liste

12-12-2018

Propofol 2% (20 mg/1 ml) MCT Fresenius

Rote - Liste